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Clinical Hyperthermia and Irradiation
Pilot studies
John Fazekas, MD* and Ted Nerlinger, BS*

Phase / (February 1979-May 1980) of our hyperthermia
pilot study involved 26 carcinoma patients who participated in two treatment protocols: 20 patients received
electron beam x-ray therapy plus an average of eight
hyperthermia sessions (twice weekly at 42.5°-43.5°C intralesional temperatures for 40 minutes); 17 patients were
heated with a 3450 microwave MHz generator in conjunction with surface heating (circulating water bag at 45°C).
AGA thermograms assessed superficial blood flow to document heating patterns and forewarned of potential overheating as manifested by superficial burns (blisters).

50% (6 of 11) among those patients who were being
retreated at the chest wall for a recurrence of breast carcinoma following
mastectomy and radiation
therapy.
Among this largest group, the combined response (CR and
PR) was an ecouraging 8 of 11, with an average follow-up
time of five months. Among the 22 cases that could be
evaluated, the response varied; six had a complete response, five a partial response, and 11 a combined response (50%). The results ofthis pilot study are sufficiently
encouraging to consider expanding potential eligible cases
to include deep-seated tumors within the pelvis, lung apex,
or deep muscular (extremity) regions.

Although our study Is nonrandomized and our patient
numbers are small, we noted a complete response (CR) of

It has been unequivocally demonstrated that hyperthermia
can be an adjuvant to irradiation in the laboratory (1,2).
Under experimental conditions, a significant enhancement
in radiation cell-kill has been noted (3,4), depending upon
the cell system, radiation dose fraction, and timing of x-ray
and heat dosage (time-duration and centigrade degrees
sustained). Although it is not fully understood how hyperthermia enhances the effect of irradiation, four mechanisms
may be involved: 1) interference with repair of sublethal
radiation damage; 2) production of lethal cell membrane
damage (perhaps independent of irradiation); 3) direct
cellular lethality (especially those cells at low pH and those
in the S-phase ofthe mitotic cycle); and 4) "other" effects,
which are poorly understood and not well documented.

quency (RF) and/or microwave heating sources. Only
superficial localized or limited regional tumor masses were
considered for treatment, regardless o f t h e histologic subtype or organ of origin. Ultrasonic heating techniques, as
reported by Marmor, et al (7), have not been developed at
our institution, but they are in the planning stage.

Materials and Patients Selected
Between February 1979 and May 1980, 26 patients participated in the clinical hyperthermia program. Criteria for
selection and acceptance i n c l u d e d : 1) histologically
proven malignancy (a biopsy was not performed on every
metastatic nodule/mass); 2) clinical failure with all other
reasonable therapeutic measures (surgery, prior radiotherapy, chemotherapy/hormones); 3) capability of
heating the tumor mass with existing equipment (RF-microwave) to 42.5°C (intralesional) for 35-40 minutes for six
heat sessions. Previous radiotherapy treatment (even to
"tolerance" doses of 5000-6000 rad) was not considered a
contraindication.

Our report describes the clinical hyperthermia trial at
Thomas Jefferson University Hospital, which used hyperthermia as an adjuvant to irradiation to treat superficial,
advanced, inoperable tumor masses. With a method similar to that of Luk (5) and Kim, et al (6), we used radiofre* Department of Radiation Therapy and Nuclear Medicine, Thomas Jefferson University Hospital, Philadelphia, PA

Pretreatment evaluation included assessment of tumor volume with ultrasound techniques, CT scanning, and appropriate radiographic studies. An AGA thermographic camera
photographed the superficial vascularity in each treated

Address reprint requests to Dr. Fazekas, Department of Radiation Therapy
Thomas Jefferson University Hospital, 1025 Walnut St, Philadelphia, PA
19107
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area before and after the heat sessions, so that we might
predict areas that would heat readily or overheat (large
ischemic tumor masses tend to act as heat "sinks").

Chest wall recurrences (failure of surgery, radiotherapy, and
chemotherapy) accounted for 11 of the 22 cases. Six of
these patients had a complete response, while three additional patients experienced a partial response. Only two
failures were noted in this group. The average radiation
dosage was 2750 rad combined with an average of seven
heat sessions, two per week for one month.

Since we hoped to capitalize on the altered (hypoxicacidic) status of tumor cells after irradiation (especially
after sublethal radiation events), we administered x-ray
therapy first, followed by heat, generally according to this
protocol sequence:

The second largest group submitting to hyperthermia (nine
patients) consisted of those with superficial, metastatic skin
nodules of lymph nodes secondary to squamous carcinoma
arising in the head and neck fthree cases) or in the lung
(six). Of these, three had a partial response, while no
response was observed in six cases. A third group of six
patients had tumors at various sites, which included primary carcinomas in the colon, ovary, skin (melanoma) and
l y m p h nodes (histologic l y m p h o m a ) , or soft tissues
(liposarcoma).

1) Electron beam therapy, 200-250 rad to volume, 4
fractions/week;
2) "Immediate" hyperthermia of 42.5°-43.5°C (intralesional) X 40 minutes twice weekly;
3) Repeat cycle q. week for total of 3000-5000 rad and
6-8 heat treatments.
Using Bailey thermocouple equipment, we measured temperatures during heat therapy every five minutes with the
RF or microwave source off for 15-30 seconds. While the
patient was under local anesthesia, an 18G plastic intracatheter was inserted directly w i t h i n the t u m o r mass,
placed at different depths with each heating session (0.5
cm, 1.0 cm, 1.5 cm). We also monitored surface temperature readings beneath a thin plastic bag of circulating hot
water maintained at 45°C. Circulating cold ice water was
added to the skin surface when inadvertent overheating
caused a second degree burn (blister) or when post-treatment AGA thermograms showed an area of skin heating
that exceeded 45°C.

The first five patients treated (Table I) were heated with RF
techniques (18-25 MHz), with applicators placed directly
over the skin surface and insulated from the skin by plastic
materials. Unfortunately, these "capacitor-RF" techniques
led to skin blisters in every case despite attempts to prevent
skin burning. The remaining patients were heated by external heat applicators raised 2-5 cm from the skin surface. A
2450 microwave generator (maximum output of 100 W)
was used for these patients, while a 27.12 MHz ridge
waveguide (RCA) applicator was used in the remaining
three cases (cases 6, 8, 11). Among this larger group of 21
patients, we did not observe any significant skin complications, late effects, or enhanced reaction from radiation.

Results
Table I summarizes the treatment parameters for 26 patients treated with hyperthermia by May 20, 1980. Five
patients who could not receive additional radiation therapy
were treated with heat alone (cases 1, 7, 8, 11, and 13).

Summary
We will soon expand our program to include candidates
with inoperable, recurrent, and previously treated tumors
located within the lower pelvis (prostate, bladder, rectum,
cervix) in a phase 1-11 trial of the 27.12 MHz ridge waveguide applicator. With the hand-held 2450 waveguide
applicator, we can achieve intralesional temperatures of
43.0°C ± 0.5°C while keeping the surface at 40.0°-41.0°C
by rotating the unft to avoid uneven heating.

O f t h e 22 cases that were available for evaluation by the
end ofour pilot study, six experienced acomplete response
(disappearance of all tumor on sight and palpation), and
five had a partial response (>50% tumor shrinkage). Eleven
of the 22 had no response, as measured by < 5 0 % tumor
shrinkage.
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TABLE I
Case #
Age/Sex

Date
Rx

Primary
Site

Area
Treated

Method
(A)

No. of
(A)Tx

Radiation
Therapy

Results

1.

49 F

2/79

oropharynx

6 X 9 x 35 c m

RF alone

4

None

response < 5 0 %
died of Ca

2.

69 F

2/79

adenoca,
breast

35 X 35 c m
chest wall

RF + XRT

9

875/4

blister, NR

3.

35 M

4/79

tongue,
squamous

large cerv.
nodes

RF -1- XRT

5

400/4

response < 5 0 % ,
blister,
died 3 mo

4.

59 F

5/79

adenoca,
breast

mult, nodules
chest wall

XRT -1- RF

10

1100/4

5.

65 F

5/79

adenoca,
breast

4 c m mass
chest wall

XRT + RF

6.

64 F

7/79

sarcoma

>10 X15 cm
buttocks

XRT -127 MHz

7.

66 F

10/79

adenoca,
breast

1.5 X 1 c m
chest wall

8.

72 F

9/79

adenoca,
colon

9.

58 F

12/79

10.

58 M

11.

2

400/2

regression
of n o d u l e s
> 5 0 % , d i e d 1 yr

10

500/5

NR

9

2750/11

softer, but
NR

45°C H2O -H
2450 MHz

8

None

CR, alive and
well at 7 m o

10 X 1 0 c m

27 MHz

7

None

b l e e d i n g and
size u n c h a n g e d

adenoca,
breast

1.0 X 1.4 c m
chest wall

XRT -145°C H2O -12450 MHz

10

5000/20

response > 5 0 % ,
alive and well
at 5 mo

1/80

oropharynx,
squamous

> 1 0 c m skin
(cerv) mass

XRT -12450 MHz
(Re-treat)

8

3750/17

response > 5 0 %

4

1600/4

alive a* 5 m o

50 M

7/79

melanoma,
skin

4 cm
lymph nodes

XRT + A

2

4400/22

died of d i s s e m .
Ca

12.

53 F

12/79

adenoca,
breast

chest wall
(mult, nod.)

XRT + 45°C
H2O •¥ 2450 MHz

7

4400/22

CR, NED 5 mo

13.

73 M

1/80

lung

5 X 8 cm
supraclav. mass

45°C H2O -12450 MHz

None

NR, d i e d 4/80

14.

55 F

1/80

adenoca,
breast

2.6 X 1.5 c m
chest wall
nodules

XRT -h45°C
H2O + 2450
MHz

8

5400/27

CR, alive and
well, 4 mo

15.

66 M

1/80

lung,
squamous

supraclav.
recurrent,
squamous

XRT -1- 45°C
H2O •+• ice
H2O + 2450

8

3600/18

> 5 0 % , alive and
well, 4 mo

16.

63 F

1/80

adenoca,
breast

chest wall

XRT -1- 45°C
H2O -1- 2450

6

4035/17

GR, alive and
well, 5 mo

17.

42 F

2/80

lung,
squamous

6 c m post,
cerv. mass

XRT -H 45°C
H2O -1- 2450

8

4250/17

> 5 0 % response,
pain g o n e

ts.

62 F

3/80

adenoca,
breast

mult,
chest wall

XRT + 45°C
H2O -1- 2450

8

3000/10

CR at 1 m o

19.

65 F

4/80

adenoca,
breast

4 c m sternal
mass

XRT + 45°C
H2O -1- 2450

7

3000/12

CR, alive and
well at 3 m o

20.

48 M

4/80

lung,
squamous

6 X 5 c m mass
left neck

XRT -1- 45°C
H2O -F 2450

5

2599/10

NR, pt. d i e d
d u r i n g Rx

21.

55 F

4/80

ovary

10 c m cutaneous mass

XRT -1- 45°C
H2O -F 2450

1

300/1

NP, pt.
admitted

22.

70 M

5/80

adenoca,
lung

10 c m post,
chest wall mass

XRT -1- 45°C
H2O -1- 2450

6

2800/14

response < 5 0 %

23.

71 M

5/80

adenoca,
lung

8 x 6 cm
supraclav.

XRT -1- 45°C
H2O + 2450

6

2750/11

response < 5 0 %

24.

76 F

5/80

histiocytic
lymphoma

2.5 x 2.5 c m
nasal cavity mass

XRT + 45°C
H2O + 2450

3

1200/6*

—

25.

54 F

5/80

skin,
melanoma

4 x 3 cm
subcutaneous
masses

XRT -1- 45''C
H20 + 2450

3

1200/3*

—

26.

50 F

5/80

adenoca,
breast

15 X 1 2 c m
chest wall ulcer

XRT + 45°C
H2O -1- 2450

(Re-treat)

A = heat
RF = radiofrequency
XRT = x-irradiation

CR = complete response, disappearance of tumor
PR = partial response, > 5 0 % tumor shrinkage

26

10

1

200/1*
NR = no response, < 5 0 % tumor shrinkage
* Patients currently under therapy
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